Fuchs, Beth BurgwynRajamuthiah, RajmohanSouza, Ana Carolina RemondiEatemadpour, SorayaRossoni, Rodnei Dennis [UNESP]Santos, Daniel AssisJunqueira, Juliana C [UNESP]Rice, Louis BMylonakis, Eleftherios2018-12-112018-12-112016-02-01Future Medicinal Chemistry, v. 8, n. 2, p. 117-132, 2016.1756-89271756-8919http://hdl.handle.net/11449/177804Background: We identified auranofin as an antimicrobial compound utilizing a high-throughput screen using a Caenorhabditis elegans-Staphylococcus aureus infection model. Results/methodology: Treatment of infected nematodes with auranofin resulted in a prolonged survival rate of 95%, reached with 0.78 μg/ml. Further investigation of the antimicrobial activity of auranofin found inhibition against S. aureus, Enterococcus faecium and Enterococcus faecalis. Importantly, the fungal pathogens Cryptococcus neoformans was also effectively inhibited with an MIC at 0.5 μg/ml. Auranofin appears to target the thioredoxin system. Conclusion: This work provides extensive additional data on the antibacterial effects of auranofin that includes both reference and clinical isolates and reports a novel inhibition of fungal pathogens by this compound.117-132engantimicrobialauranofinBucillus subtilisCandida albicansCryptococcus neoformansEnterococcus faecalisEnterococcus faeciumStaphylococcus aureusArtigo10.4155/fmc.15.182Acesso restrito2-s2.0-84958050404